Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
79.45 EUR | -1.06% | +0.51% | +1.00% |
Apr. 02 | Bernstein starts AstraZeneca at 'outperform' | AN |
Feb. 22 | Transcript : Kerry Group plc Presents at 2024 Consumer Analyst Group of New York Conference, Feb-22-2024 10:00 AM |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.08% | 14.91B | A- | ||
-3.33% | 271B | A- | ||
-2.31% | 95.17B | C+ | ||
+3.00% | 46.28B | C+ | ||
+1.57% | 40.93B | B- | ||
+8.72% | 39.98B | B- | ||
+0.36% | 38.2B | B- | ||
-5.40% | 28.94B | A | ||
+15.38% | 25.4B | A- | ||
-10.01% | 22.48B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KRZ Stock
- Ratings Kerry Group plc